Bombardier (OTCMKTS:BDRBF) Cut to Neutral at JPMorgan Chase & Co.

Share on StockTwits

JPMorgan Chase & Co. cut shares of Bombardier (OTCMKTS:BDRBF) from an overweight rating to a neutral rating in a research note released on Friday morning, The Fly reports.

Several other equities analysts have also weighed in on the stock. Goldman Sachs Group lowered shares of Bombardier from a buy rating to a neutral rating and dropped their price objective for the company from $3.75 to $2.00 in a report on Friday, August 16th. Desjardins lowered shares of Bombardier to a buy rating in a report on Friday, August 2nd. Five equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $2.00.

Shares of OTCMKTS BDRBF opened at $1.42 on Friday. The firm’s 50-day moving average price is $1.37 and its 200-day moving average price is $1.70. Bombardier has a 1-year low of $1.16 and a 1-year high of $3.69.

Bombardier Company Profile

Bombardier Inc, together with its subsidiaries, manufactures and sells transportation equipment worldwide. The company operates in four segments: Business Aircraft, Commercial Aircraft, Aerostructures and Engineering Services, and Transportation. The Business Aircraft segment designs, manufactures, and markets business jets, as well as provides aftermarket support services.

Featured Story: Cost of Capital Explained

The Fly

Analyst Recommendations for Bombardier (OTCMKTS:BDRBF)

Receive News & Ratings for Bombardier Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bombardier and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SOTHERLY HOTELS/SH SH  Upgraded by Zacks Investment Research to Hold
SOTHERLY HOTELS/SH SH Upgraded by Zacks Investment Research to Hold
Solaredge Technologies  Lowered to Hold at Zacks Investment Research
Solaredge Technologies Lowered to Hold at Zacks Investment Research
Resonant  Upgraded to “Hold” at Zacks Investment Research
Resonant Upgraded to “Hold” at Zacks Investment Research
Portola Pharmaceuticals  PT Lowered to $44.00
Portola Pharmaceuticals PT Lowered to $44.00
UltraNote Coin Reaches Market Cap of $13,486.00
UltraNote Coin Reaches Market Cap of $13,486.00
FS KKR Capital Corp  Receives $7.63 Consensus PT from Analysts
FS KKR Capital Corp Receives $7.63 Consensus PT from Analysts


© 2006-2019 Ticker Report